Coronavirus disease 2019 (COVID-19) complicated by Spontaneous Pneumomediastinum and Pneumothorax

Megan Gillespie a,⁎, Nathan Dincher a, b, Pamela Fazio c, Onyinyechukwu Okorji a, c, Jacob Finkle b, Argun Can b

a Department of Emergency Medicine, Jefferson Health - Northeast, Philadelphia, PA, USA
b Department of Critical Care, Jefferson Health - Northeast, Philadelphia, PA, USA
c Department of Internal Medicine, Jefferson Health - Northeast, Philadelphia, PA, USA

⁎ Corresponding author. Graduate Medical Education Office, % Mary Allegrini, 10800 Knights Road, Philadelphia, PA, 19114, USA.
E-mail address: megan.gillespie@jefferson.edu (M. Gillespie).

https://doi.org/10.1016/j.rmcr.2020.101232
Received 26 May 2020; Accepted 19 September 2020
Available online 23 September 2020
2213-0071/© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The first reports of severe acute respiratory symptoms from a novel coronavirus called coronavirus disease 2019 (COVID-19) occurred in Wuhan, Hubei Province, China in December 2019. The World Health Organization (WHO) named the infections caused by this virus coronavirus disease 2019 (COVID-19). The WHO declared the current COVID-19 outbreak a global pandemic on March 2020. The COVID-19 outbreak has resulted in a current global health emergency. Clinical information about the findings of COVID-19 and its associated complications are constantly evolving and becoming more widely available. Providers should be familiar with both typical symptoms and image study results for COVID-19 as well as less commonly reported complications of progressive COVID-19, such as spontaneous pneumomediastinum and spontaneous pneumothorax as highlighted in this case.

2. Case report

A 70-year-old male with a past medical history of hypertension and hyperlipidemia presented to the emergency room by ambulance with chills, nonproductive cough, shortness of breath, chest pain, loss of taste, and dizziness. He denied ever smoking, denied recent travel, but did admit to being around co-workers who felt ill.

On initial evaluation, the patient was afebrile and hemodynamically stable. He was in moderate respiratory distress with tachypnea and with a pulse oximetry reading of 89% on 15L/min supplemental oxygen by non-rebreather mask. The patient’s initial labs demonstrated a positive qualitative polymerase chain reaction assay for SARS-CoV-2, hyponatremia at 129 mmol/L, elevated aspartate aminotransferase measuring 47 ssdU/L, elevated lactate dehydrogenase at 778 U/L, elevated C-Reactive Protein at 12.16 mg/dL, elevated ferritin level of 1597 ng/mL, and D-dimer measuring 284 ng/mL. The patient’s remaining labs including complete blood count, the remainder of the comprehensive metabolic panel, lactate, and creatine phosphokinase were all within normal limits. The patient’s initial chest x-ray (CXR) demonstrated no acute abnormalities, no infiltrate or effusion (Fig. 1). The patient was placed on mid-flow nasal cannula supplemental oxygen at 15L/min and he was admitted to the hospital for treatment of COVID-19.

The patient continued to decline clinically with increasing oxygen requirements despite initiation of hydroxychloroquine and high dose dexamethasone. On day seven of the patient’s hospitalization, he was found to be more tachypneic and hypoxic requiring transition to supplemental oxygen of 50L/min by high-flow nasal cannula.

Chest x-ray was repeated on this seventh day of his hospitalization, bilateral patchy airspace disease were noted, all new findings compared to his initial chest x-ray. The patient continued to decline clinically with increasing oxygen requirements despite initiation of hydroxychloroquine and high dose dexamethasone. On day seven of the patient’s hospitalization, he was found to be more tachypneic and hypoxic requiring transition to supplemental oxygen of 50L/min by high-flow nasal cannula.

On initial evaluation, the patient was afebrile and hemodynamically stable. He was in moderate respiratory distress with tachypnea and with a pulse oximetry reading of 89% on 15L/min supplemental oxygen by non-rebreather mask. The patient’s initial labs demonstrated a positive qualitative polymerase chain reaction assay for SARS-CoV-2, hyponatremia at 129 mmol/L, elevated aspartate aminotransferase measuring 47 ssdU/L, elevated lactate dehydrogenase at 778 U/L, elevated C-Reactive Protein at 12.16 mg/dL, elevated ferritin level of 1597 ng/mL, and D-dimer measuring 284 ng/mL. The patient’s remaining labs including complete blood count, the remainder of the comprehensive metabolic panel, lactate, and creatine phosphokinase were all within normal limits. The patient’s initial chest x-ray (CXR) demonstrated no acute abnormalities, no infiltrate or effusion (Fig. 1). The patient was placed on mid-flow nasal cannula supplemental oxygen at 15L/min and he was admitted to the hospital for treatment of COVID-19.

The patient continued to decline clinically with increasing oxygen requirements despite initiation of hydroxychloroquine and high dose dexamethasone. On day seven of the patient’s hospitalization, he was found to be more tachypneic and hypoxic requiring transition to supplemental oxygen of 50L/min by high-flow nasal cannula.

Chest x-ray was repeated on this seventh day of his hospitalization, bilateral patchy airspace disease were noted, all new findings compared
to CXR on initial presentation (Fig. 2). With these new findings on portable CXR, the patient had a computed tomography (CT) chest without IV contrast performed that also demonstrated extensive pneumomediastinum and bilateral ground-glass opacities, but no pleural or pericardial effusion, no pneumothorax, and no lymphadenopathy (Fig. 3).

Several days later, the patient continued to have worsening respiratory status despite maximum supplemental oxygen therapy via high-flow nasal cannula and he was found to have a significantly elevated D-dimer prompting initiation of anticoagulation with heparin infusion and a CT angiogram (CTA) chest. CTA chest demonstrated extensive ground-glass opacities, pneumomediastinum, subcutaneous emphysema in the neck, and a new finding of a small right pneumothorax (Fig. 4A and B). The patient eventually required endotracheal intubation for respiratory failure. Repeat imaging showed resolution of small right pneumothorax but continued pneumomediastinum. The patient’s clinical status continued to deteriorate and after discussion with family the decision was made to palliatively extubate the patient.

3. Discussion

This case report highlights two infrequently noted complications of COVID-19, first, spontaneous pneumomediastinum, and second, spontaneous pneumothorax. There have only been a handful of documented COVID-19 cases complicated by spontaneous pneumomediastinum and/or spontaneous pneumothorax [2–10].

Pneumomediastinum, free air in the mediastinum, can be classified as either primary, spontaneous, or secondary from chest trauma or invasive procedures [11–14]. Spontaneous pneumomediastinum, as the case in this patient presented, is a rare diagnosis [11,12]. The pathophysiology causing spontaneous pneumomediastinum is referred to as the “Macklin effect” and is described in three steps: first, alveolar rupture occurs due to increased intrathoracic pressure, next, released alveolar air centripetally dissect and tracks along bronchovascular sheaths, and finally, pulmonary interstitial emphysema tracks towards the hilum into the mediastinum [11,13–15].

The patient presented in this case with COVID-19 complicated by spontaneous pneumomediastinum likely had increased intrathoracic pressure generated from coughing compounded with fragile alveolar walls due to diffuse alveolar cell damage and death from SARS-CoV-2 preference to infect alveolar type II cells assuming SARS-CoV-2 behaves similarly to severe acute respiratory syndrome coronavirus (SARS-CoV) and influenza viruses [16,17]. The subsequent finding of spontaneous pneumothorax this patient had on repeat CT imaging is likely a complication of spontaneous pneumomediastinum with released alveolar air being trapped in the pleural cavity [11,16].

4. Conclusion

The COVID-19 outbreak has resulted in a current global health emergency. It is important for providers to be familiar with both typical
symptoms and image study results for COVID-19 as well as less sema, and a small right pneumothorax in axial plane. CTA chest demonstrated extensive ground-glass opacities, mediastinal emphysema in the neck, and a small right pneumothorax in coronal plane. B) Fig. 4.

M. Gillespie et al. commonly reported complications of progressive COVID-19, such as spontaneous pneumomediastinum and spontaneous pneumothorax found in this case.

CRediT authorship contribution statement

Megan Gillespie: Writing - original draft, Writing - review & editing. Nathan Dincher: Writing - review & editing. Pamela Fazio: Writing - review & editing. Onyinyechukwu Okorji: Writing - review & editing.

Jacob Finkle: Writing - review & editing. Argun Can: Writing - review & editing. Supervision.

Declaration of competing interest

None for any of the authors to disclose; no grants or funds received in conjunction with this project; and, this case has never been published, or presented elsewhere.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.rmcr.2020.101232.

References

[1] The World Health Organization, Coronavirus disease 2019 (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019, (Accessed 3 May 2020).
[2] R. Bhat, A. Hamid, J. Kunin, et al., [Ahead of print]. Chest imaging in patients hospitalized with COVID-19 infection - a case series, Curr. Probl. Diagn. Radiol. (2020), https://doi.org/10.1067/j.cpradiol.2020.04.001.
[3] L. Fan, D. Li, H. Xue, et al., [Ahead of print]. Progress and prospect on imaging diagnosis of COVID-19, Chin J Acad Radiol (2020), https://doi.org/10.1007/s12258-020-00031-5.
[4] P. Lei, Z. Huang, G. Liu, et al., [Ahead of print]. Clinical and computed tomographic (CT) images characteristics in the patients with COVID-19 infection: what should radiologists need to know? J. X Ray Sci. Technol. (2020) 1–13, https://doi.org/10.1002/jxsr.2020117. Clin Imag. 2020.
[5] N. Chen, M. Zhou, X. Dong, et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet 395 (10223) (2020) 507–513, https://doi.org/10.1016/S0140-6736(20)30211-7.
[6] S. Salehi, A. Abedia, S. Balakrishnan, A. Gholamrezaehad, [Ahead of print]. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients, AJR Am. J. Roentgenol. 215 (2020) 1–7, https://doi.org/10.2214/ AJR.20.23034.
[7] C. Zhou, C. Gao, X. Xie, M. Xu, COVID-19 with spontaneous pneumomediastinum, Lancet Infect. Dis. 20 (4) (2020) S10. https://doi.org/10.1016/S1473-3099(20)30156-0.
[8] R. Sun, H. Liu, X. Wang, Mediastinal emphysema, giant bulla, and pneumothorax developed during the course of COVID-19 pneumonia, Korean J. Radiol. 21 (5) (2020) 541–544, https://doi.org/10.3348/kjr.2020.0180.
[9] F. Yang, S. Shi, J. Zhu, J. Shi, K. Dai, X. Chen, [Ahead of print]. Analysis of 92 deceased patients with COVID-19, J. Med. Virol. (2020), https://doi.org/10.1002/jmv.25891.
[10] X. Yang, Y. Yu, J. Xu, et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Resp Med 8 (5) (2020) 475–481, https://doi.org/10.1016/S2213-2600(20)30079-5.
[11] R.D. Marasco, D. Loizzi, N.P. Ardo, F.N. Fatone, F. Sollitto, Spontaneous pneumomediastinum after electronic cigarette use, Ann. Thorac. Surg. 105 (2018) 269–271, https://doi.org/10.1016/j.athoracsur.2017.12.037.
[12] A.E. Newcomb, C.P. Clarke, Spontaneous pneumomediastinum, Chest 128 (5) (2005) 3298–3302, https://doi.org/10.1378/chest.128.5.3298.
[13] S. Murayama, S. Gibo, Spontaneous pneumomediastinum and Macklin effect: overview and appearance on computed tomography, World J. Radiol. 6 (11) (2014) 850–854, https://doi.org/10.4329/wjr.v6.i11.850.
[14] V.K. Kouritas, K. Papagiannopoulos, G. Lazaridis, et al., Pneumomediastinum, J. Thorac. Dis. 7 (Suppl 1) (2015) 544–549, https://doi.org/10.3978/j.issn.2072-1439.2015.01.11.
[15] M.T. Macklin, C.C. Macklin, Malignant interstitial emphysema of the lungs and mediastinum as an important occult complication in many respiratory diseases and other conditions: an interpretation of the clinical literature in the light of laboratory experiment, Medicine 23 (4) (1944) 281–358.
[16] R.J. Mason, Pathogenesis of COVID-19 from a cell biologic perspective, Eur. Respir. J. 55 (4) (2020) 2000607, https://doi.org/10.1183/13993003.00607-2020.
[17] Z. Xu, L. Shi, Y. Wang, et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med 8 (2020) 420–422, https://doi.org/10.1016/S2213-2600(20)30076-X.